Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0002-9149(01)01490-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adverse events and paramedic interventions during extended ground transport in a rural pharmaco-invasive STEMI program.
Emerg Med Australas
February 2025
Orange Health Service, Western NSW Local Health District, Dubbo, New South Wales, Australia.
Objective: Although guidelines recommend angiography and coronary intervention occur within 24 h of thrombolysis when percutaneous coronary intervention (PCI) is not available within 120 min, this target is difficult to achieve in rural and remote areas of New South Wales (NSW), Australia.
Methods: In this is secondary analysis we examine the impact of extending the existing 90-min road transport limit for patients in rural and remote areas of western NSW who have received initial treatment for ST-elevation myocardial infarction.
Results: The patient cohort consisted of 86 patients who were transported by road ambulance with transport times more than 90 min.
Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure.
ESC Heart Fail
January 2025
Division of Cardiology, Osaka Rosai Hospital, Osaka, Japan.
Aims: Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone.
Methods And Results: We enrolled 114 consecutive acute decompensated heart failure (ADHF) patients with a left ventricular ejection fraction (LVEF) of less than 50%.
Aims: Large-scale, real-world data on early initiation of sacubitril/valsartan in patients newly diagnosed (de novo) with HF with reduced ejection fraction (HFrEF) are limited. We examined the effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on all-cause and cause-specific hospitalizations among patients with de novo HFrEF from the Optum® dataset in the United States.
Methods: This retrospective cohort study included adult patients with de novo HFrEF (diagnosed ≤30 days) with left ventricular ejection fraction (LVEF) ≤40% who were first prescribed with sacubitril/valsartan or ACEi/ARB from 1 January 2016 to 31 March 2020.
PR Interval as a Valuable Predictor of Tilt Table Test Results in Patients With Neurally Mediated Syncope.
Ann Noninvasive Electrocardiol
March 2025
Department of Cardiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Background: Neurally mediated syncope (NMS) is the primary cause of temporary and self-limiting loss of consciousness. The tilt table test (TTT) has been consistently employed as a supplementary diagnostic tool for syncope evaluation. However, TTT requires specialized equipment, which is lacking in several emergency room and clinic environments.
View Article and Find Full Text PDFThe Effects of Resigning GPs on Patient Healthcare Utilization and Some Implications for Health.
Health Econ
January 2025
RWI Essen, Essen, Germany.
We study the effects of general practitioners' (GPs') resignations on their patients' healthcare utilization and diagnoses in an event-study setting. Using claims data from a large German statutory health insurance, we find that after physicians leave, their former patients persistently reduce their primary care utilization, only partially substituting it with specialist visits and hospital care. Because patients find a new GP already 1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!